"A network composed of comprehensive cancer centers and university hospitals with expertise in oncology. The centers closely work together to contribute to a common project"
Our organization is based on interactions between all entities composing the network: investigators, industries, patients, scientists.
We are all “working together” to improve patient outcomes!
The role of the Operational Team is to manage the day-to-day management of activities.
The Steering Committee has the responsibility of strategic decisions and is composed of one representative per Oncodistinct center.
The Coordinating Team is composed of physicians elected by the Steering Committee and implements the decisions of the Steering Committee.
The driving force of the Oncodistinct Network is firmly its Investigators’ Think Tank. It is the forum for scientific discussions, ideas and strategies which brings innovative clinical research projects. The think tank is composed by a large panel of experts in cancer care (investigators, scientists…) involved in drug development.
Ali Shamseddine, MD, FRCP is a Professor of Medicine in Oncology, Head of the Department of Hematology- Oncology, Director of the data management and clinical research unit, and the Tumor registry at the Naef Basile Cancer center in the American University of Beirut Medical Center. His research focuses on Epidemiology, Gastrointestinal and Urology cancers. He has over 180 articles in scientific journals and serves as a reviewer for many journals. Dr. Shamseddine lectured and chaired national and regional medical sessions. He was the past Chairman of the Hospital Committee on Cancer at AUBMC, and the past President of the Lebanese Society of Hematology.
Jean-Luc CANON is Medical Oncologist and head of the Cancer Center at the Grand Hôpital de Charleroi in Charleroi, Belgium.
His mean topics of interest are breast Cancer, translationnel research and development of new drug.
He is member of several national and international scientific societies (ASCO, EORTC, ESMO, Unicancer).
He is the author or co-author about 250 articles or abstracts in international journals.
Prof. Anthony Gonçalves is a medical oncologist at the Comprehensive Cancer Center Institute Paoli-Calmettes (IPC), Marseille, France. Head of the Department of Medical Oncology, he is leading the metastatic breast cancer program. At IPC, he is also co-chairing the early phase trial unit, in charge of developing innovative medical therapeutics for solid tumor patients.
Since 2013, he is Professor of Oncology at the Medical School of La Timone, Marseille, Aix-Marseille University. He is an active member of ESMO and ASCO. He is a member of the Steering Committee of the Unicancer Breast Cancer Group. Prof. Gonçalves has published more than 200 papers in peer-reviewed journals in the domain of basic, translational and clinical oncology.
Head of department of medical oncology and member of the directory board of the oncology center, Institut Roi Albert II, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels Belgium.
Training : Johns Hopkins School of Medicine, Baltimore USA (Fellow in Medical Oncology 1998-2000) and Université catholique de Louvain, Brussels, Belgium (MD: 1993; PhD: 2001).
Main interests: Head and Neck cancer, translational research, and early clinical trials (phase 1).
Medical oncologist graduated from the Université Libre de Bruxelles, 1990, training at Brussels Institut Jules Bordet Cancer Center, research fellow Lombardi Cancer Center, Georgetown University. PhD thesis on Hypoxic stress regulated NK cell immune response at University Paris Sud. In 2003 founded the Laboratory of Experimental Cancer Research at Luxembourg Institute of Health. Clinical position Staff Oncologist at Centre Hospitalier in Luxembourg where he heads the Oncology Platform. Clinical work lung cancer and neurooncology. Labwork on cell death mechanisms in hematology, immunooncology and personalized medicine. President of Luxembourg National Institute of Cancer, Luxembourg Society of Oncology and MSF Luxembourg. CAT delegate at EMA.
Philippe Barthélémy is medical oncologist in the Department of medical oncology at the University hospital of Strasbourg and the Comprehensive Cancer Center of Strasbourg in France.
Doctor Philippe Barthélémy was born in Luxembourg and did his internship at the University hospital of Strasbourg, France. He obtained his degree of doctor of medicine in 2009 and his thesis of sciences in molecular biology in 2016 at the University of Strasbourg. During his specialization in medical oncology, he also followed trainings in the clinical development of new anticancer drugs at the Jules Bordet Institute in Brussels (under the supervision of Professor Ahmad Awada).
He has an important clinical activity in the treatment of solid tumors and in particular genitourinary cancers.
He co-leads the early drug development unit of the “Institut de cancérologie strasbourg europe “. Furthermore he’s head of the molecular tumor board in Strasbourg.
Dr Barthélémy is ESMO member, French GETUG group and Unicancer Breast cancer intergroup member.
Diego Tosi, MD, PhD, serves as Head of the Early Clinical Trial Unit at the Institut du Cancer de Montpellier (France). He graduated in 2000 from the University of Milan Medical School (Italy), where he trained on Medical Oncology, and obtained a PhD Degree in Cellular Biology from the University of Montpellier in 2016. His clinical research activity focuses on new drug development in solid tumors patients, and on monoclonal antibody pharmacology. He conducts an intense preclinical research activity, focused on rational development of drug combinations, mainly through tumor adaptive response analysis. Since 2011 he is program lead in the MAbImprove Consortium for the development of monoclonal antibodies.
Dr Peter Vuylsteke obtained his Medical Oncology degree at the University of Leuven, Belgium, and is active as an oncologist in CHU UCL Namur, Site St-Elisabeth, Belgium. His medical interests are in Breast cancer, Gynaecological cancer and affordable care.
He is a member of the steering committee of the EORTC breast Cancer trial group, member of the ESMO Faculty for Breast Cancer, and vice-president of the Belgian society of Medical Oncology.
Tormod Kyrre Guren (MD, PhD) is Specialist in Medical Oncology and Radiation Therapy in Oslo, Norway. Since 2010, Dr. Guren works as a Senior Consultant at the Clinical Trial Unit, Department of Oncology, Oslo University Hospital/Oslo Comprehensive Cancer Centre.
His clinical practice is mainly focused on treatment of cancer patients in early clinical trials, and he has more than 15 years of experience as principal investigator. As an associated investigator at the K.G. Jebsen Colorectal Cancer Research Centre, Dr. Guren is involved in several translational research projects on lower gastrointestinal cancers. He serves as a member of The Norwegian Board of Medical Experts for Patients with Life Threatening Diseases and he is a member of ESMO and ASCO.
Dr Deborah Mukherji joined the faculty of the American University of Beirut in June 2012 as a medical oncologist and has a special interest in GI and GU oncology. Dr Mukherji completed her advanced specialty training in Medical Oncology at Guys and St Thomas’s NHS Foundation Trust, London UK and was awarded a Post-Graduate Diploma in Oncology from the Institute of Cancer Research, University of London in 2011.
On completion of her advanced specialty training Dr Mukherji joined the Royal Marsden Hospital London where she worked with Professor Johann De Bono specializing in clinical research and drug development with a focus on prostate cancer. In June 2015 Dr Mukherji was awarded a post-graduate diploma in Global Clinical Research from Harvard Medical School supported by a scholarship from the Dubai-Harvard Foundation. In June 2016 Dr Mukherji was elected as a Fellow of the Royal College of Physicians UK.
Stephane Holbrechts is head of Oncology – Hematology – Palliative Care department and coordinator of the cancer care program at the university hospital Ambroise Pare (HAP) Mons Belgium. He is internship supervisor in oncology.
Mostly active as clinician, he is particularly involved in the treatment of digestive and lung cancer, holder of a European Interuniversity certificate in thoracic oncology. As researcher, he has a ten years experience as principal investigator of numerous clinical trials and is active in academic and fundamental research notably by cooperating with UMHAP (Clinical Research Center of HAP and Mons University) and ELCWP (European Lung Cancer Working Party). He is member of several scientific societies (ASCO, BSMO, BGDO).
Eric Raymond is board certified MD specialized in medical oncology and obtained a PhD degree in cellular and molecular biology, working on preclinical mechanisms of action and combinations of several novel anticancer drugs. He has been appointed as Chef de Clinique in Paris 6 Curie University with Prof. A. de Gramont for two years before undertaking a 2 year post-doctoral fellowship with Daniel D. Von Hoff at the Cancer Therapy and Research Centre and Institute for Drug Development at the University of Texas in San Antonio, USA, Then, Eric Raymond undertook clinical and translational research in phase1-2 clinical studies of early drug development at the Gustave-Roussy Institute, Villejuif, France for 7 years.
Eric Raymond has been appointed as full professor of oncology at the University of Paris VII (Denis Diderot) and chair of the Medical Oncology Department at Bichat-Beaujon University Hospitals, Clichy, France in 2004. Prof Eric Raymond was also appointed as full professor of medical oncology at the university of Lausanne in 2014. Over more than 10 years of experience as a chair of oncology in France and Switzerland, Eric Raymond developed in medical and research skill in patient care, oncology teaching, research, regulatory requirement, management, and team building. Eric Raymond specialized in various areas of drug development focusing on translational laboratory research and early clinical trials focusing on drugs and therapeutics with novel mechanisms of action. Eric Raymond developed a large number of academic- and industry-sponsored projects both in the lab and the clinic. Current focus is related to bridge preclinical and translational data to clinical applications to accelerate novel drug positioning both for safety and efficacy. Works are ongoing to develop tumour tissue-based biomarkers, liquid biopsy, and in-patient molecular imaging.
Jean-Pierre Delord is Professor in Medical Oncology at the Paul Sabatier University in Toulouse, France.
Pr Delord’s research interest focus on the biology of Ovarian, Head and Neck cancer, Pharmacology of anticancer drugs, and the relationship of the tumour micro-environment and malignant cells, and investigations of clinical applications in the field of pharmacokinetic, pharmacodynamic and phase I trials. He is also involved in pre-clinical programs of development of new compounds from basic research to early phases.
He is participating to many scientific boards of pharmaceutical companies and biotech companies, specially during pre-clinical phases of development. He is a national expert of the Minister of Research and Industry.
Pr Delord is an active/board member or expert of the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR) and has served as member of the Scientific Committee of the PAMM group.
Pr Delord has published over 100 peer-reviewed articles and over 300 abstracts in congress.
Christophe Le Tourneau is senior Medical Oncologist at the Institut Curie and Professor of Medicine at Paris-Saclay University. He is heading the Department of Drug Development and Innovation (D3i) as well as the Head and Neck Clinic. Christophe Le Tourneau was certified in Medical Oncology in 2005 and got his PhD in Clinical Epidemiology in 2007.
He did a 2-year Clinical Research Fellowship at Princess Margaret Hospital in Toronto, Canada, in the Drug Development Program. His main interests are precision medicine, phase I clinical trials with a special attention at the methodology to conduct these trials, as well as Head and Neck oncology. Christophe Le Tourneau is the principal investigator of numerous phase I and II trials, as well as of clinical trials in Head and Neck oncology. He ran the first randomized precision medicine trial (SHIVA01) that compared the efficacy of matched targeted therapy versus conventional chemotherapy in patients with advances cancer. He has published 140+ peer-reviewed papers in international journals.
Florian Clatot is a French Medical Oncologist working in the Henri Becquerel Cancer Centre in Rouen, France. His clinical activity as well as his translational research are focused on breast cancer and head and neck cancers. Dr Clatot is involved in several clinical studies as investigator or PI. Dr Clatot is an active member of several national or international scientific societies (GORTEC, EORTC, Unicancer).
Dr Panos Papanastasopoulos was appointed Consultant in Medical Oncology at the Bank of Cyprus Oncology Centre (BOCOC), in March 2017, following completion of his training at Imperial College in London, UK (2016). He treats GI malignancies, and is also responsible for the development of ‘Anastasios Leventis’ Clinical Trials Unit. He graduated from the Medical school of Patras, Greece in 2005, where he also obtained his MSc in 2009. In 2014, he obtained his Postgraduate Diploma in Oncology from the Institute of Cancer Research in London. He is a full Member of the Royal College of Physicians (UK), as well as a EORTC member and ESMO member. He regularly teaches undergraduate medical students at the University of Cyprus. He has published in peer-reviewed journals and has contributed as an author for book chapters in oncology. Finally, he has been a co-investigator in more than 30 clinical trials, and is currently the principal investigator for the EORTC 1741 DYNAMIC clinical trial in BOCOC.
Adda BOUNEDJAR is Chairman of Medical Oncology Department CHU Frantz Fanon BLIDA ALGERIA.He is Professor of Medical Oncology at Blida 1 University . He is President of Algerian Society of Training and Research in Oncology (SAFRO) And Vice president of Arab Medical Association Against Cancer (AMAAC).
He is member in MENA-NCCN steering committee and in ASCO Clinical Practice Guideline Advisory and he is also member of several international research group and scientific societies ( ACHOG, ICRG, saint paul,AMCI,BGICC,ASCO,ESMO…).he published some pubications in international journals.
Nicolas PENEL (M.D, Ph.D) is Head of Clinical Research and Innovation Department of the Oscar Lambret Cancer Center at Oscar Lambret Cancer, Lille, and North of France. This department includes early phase trial unit, day hospital dedicated to patients enrolled in clinical trials, methodology and biostatistics Unit and Regulatory/Operational Unit in charge of promoting clinical trials. As researcher in Medical School Lille University, his main expertise is methodology of early phase clinical trials, especially reporting of adverse events. As medical oncologist, his main clinical expertise is management of adult sarcoma, urinary cancers and rare cancers. Dr PENEL is member of several scientific societies (ASCO, EORTC, and CTOS). He published 223 scientific or didactic publications in international journals.
Doctor Alain HENDLISZ is a gastroenterologist. He obtained his MD (Docteur en Médecine, Chirurgie et Accouchements) at the Université Libre de Bruxelles in 1988 and his specialization in gastroenterology in 1993. From October 1993 to September 2002, he worked at the Gastroenterology Unit (Prof. Harry Bleiberg) and at the Oncology Unit (Prof. Martine Piccart) of the Jules Bordet Institute-Brussels. During 2002, he visited the Royal Marsden Hospital, Sutton, England at the Digestive Oncology department (Prof. Cunningham) as a clinical fellow supported by a grant of “Les Amis de l’Institut Bordet”. Since 2002, he is the Head of the Gastro-Enterology Unit, Medical Oncology Clinic at the Jules Bordet Institute, Anti-Cancer Center – Université Libre de Bruxelles (ULB) – Brussels – Belgium.
He is founding and currently member of the Board of the BGDO (Belgian Group for Digestive Oncology). He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the Société Royale Belge de Gastro-entérologie (SRBG) and European Organization for Research and Treatment of Cancer (EORTC).
Dr Alain HENDLISZ is also member of the editorial committee of several scientific journals including Current Opinion in Oncology. He published 89 peer-reviewed papers in international journals and chapters of books (35 as first or last author). He is involved as principal investigator or co-investigator in numerous national and international clinical studies. In 2015, Dr Hendlisz defended his PhD thesis entitled “Multimodality imaging for treatment response prediction in colorectal cancer”, and he is now Maître de Conférences at Université Libre de Bruxelles.
Dr Lore Decoster is a staff member of the department of Medical Oncology at Universitair Ziekenhuis Brussel, Brussels, Belgium. As a clinician dr Decoster has an important clinical activity in the treatment of solid tumours, with a special focus on lung cancer, breast cancer, gynaecological cancers and thyroid cancer. She is also focussing on geriatric oncology. Dr Decoster is also a researcher in these domains, in particular in lung cancer and geriatric oncology. Dr Decoster is a member of different scientific organisations including ASCO, ESMO, IASLC, BSMO and SIOG. Dr Decoster has published more than 20 articles in different peer review journals.
Giuseppe Curigliano, MD, PhD, is the Head of the Division of Early Drug Development at European Institute of Oncology, and Associate Professor of Medical Oncology and University of Milano, Italy. He is a clinician and researcher specializing in early drug development for patients with solid tumors with a special commitment on breast cancer. He is also involved in translational research related to immunotherapy, precision medicine, and biomarkers identification. He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG) Immune Task Force. He is founding member of/and scientific chair for the International Cardio-Oncology Society (ICOS). Dr Curigliano is the Chair of the ESMO Nomination Committee. He served as the scientific chair of the IMPAKT-ESMO meeting that was held in Brussels in 2014 and as “Metastatic breast cancer track chair” of the ESMO 2014 meeting in Madrid. He is an ESMO Faculty Member since 2001 for breast cancer and served on the Program Scientific Committee of the St Gallen Conference since 2011, and as Scientific Chair in St Gallen 2017. He served in the Scientific Committee for ESMO Immuno-Oncology Congress 2017, 2018 and ESMO Asia 2017 and 2018. He served as the Scientific Chair for St Gallen 2019, ESMO Asia 2018 and ESMO Breast Congress 2019. He has contributed to over 300 peer-reviewed publications and almost 20 book chapters. He also serves on the European School of Oncology (ESO) faculty committee.
He has been appointed as Editor of Annals of Oncology for the period 2014-2020, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of European Journal of Cancer and editor of the Journal of Clinical Oncology. He has been awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017.
Massimo Di Nicola is Head of the Immunotherapy and Anticancer Innovative Therapeutics Unit at Fondazione IRCCS Istituto Nazionale Tumori of Milan, Italy. He has been involved throughout his career in both clinical and pre-clinical research programs in onco-hematology, thus building from the beginning of his scientific background an experience in the field of translational medicine. He also takes an active part in the development of new therapeutic strategies (i.e., high-dose chemotherapy, vaccination with dendritic cells, molecular-targeted therapies) with some important achievements for the improvement of anticancer cure. Dr. Di Nicola is member of several international scientific societies (ASCO, ASH, ESMO, NIBIT). He published 10 book chapters and 110 scientific publications in international journals.
Francois P Duhoux, MD, PhD, is a medical oncologist at the King Albert II Cancer Institute of Cliniques universitaires Saint-Luc in Brussels, Belgium. He focuses on breast cancer and early drug development. He holds a degree in oncogenetics and is an internal consultant in the Center for Human Genetics. He is an Assistant Professor at Université catholique de Louvain and studies novel genetic factors predisposing to breast cancer. He is the president of the Belgian Society of Senology and an active member of AACR, ASCO, BeSHG, BSMO, EORTC and ESMO. He has published over 30 articles in peer-reviewed journals.
Ahmad Awada is Head of the Oncology Medicine Department at Jules Bordet Cancer Institute in Brussels, Belgium. He is Professor of Oncology Medicine at the Université Libre de Bruxelles. As a clinician, Pr. Awada has an important clinical activity in the treatment of solid tumors, in particular breast cancer. He also takes an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy), some of which are widely used. Pr. Awada is also a member of several international scientific societies (ASCO, EEORTC, ESMO). He published more than 290 scientific publications and 32 book chapters.
Philippe Aftimos, MD is a medical oncologist and the senior research physician at the Clinical Pharmacology Unit of Institut Jules Bordet in Brussels since October 2012.
Dr Aftimos has a special interest in breast cancer, new drug development and precision medicine. At Institut Jules Bordet, he supervises the phase I clinical trials program. He is also responsible for the coordination of the institutional Sequencing Tumor Board. He is co-PI of AURORA (Aiming to Understand the Molecular Aberrations of Metastatic Breast Cancer), a large European molecular screening program launched by the Breast International Group. He is also co-PI of the soon to be launched Belgian Society of Medical Oncology precision medicine program.
YUEYIN PAN is vice president of Anhui Cancer Hospital, and Head of the department of Anhui Provencial Hospital China. He is Professor of Clinical Medicine at the Anhui Medical University.
As a clinician, he has an important clinical activity in the treatment of solid tumors, in particular breast cancer and lung cancer. Pr. PAN is member of several international scientific societies. He published over 100 scientific publications in international journals.
Luis Teixeira is a Medical Oncologist at Saint Louis Hospital (APHP) in Paris, France. He is Associate Professor of Medicine at the Université Paris Diderot in Paris. As a clinician, Dr. Teixeira has an important clinical activity in the treatment of solid tumors, in particular breast cancer. He also takes an active part in the development of new drugs (cytotoxics, molecular-targeted therapies, immunotherapy). Dr. Teixeira is member of several French and international scientific societies (GERCOR, UNICANCER, ESMO). He published more than 50 scientific publications in international journals.
Demetris Papamichael is Director of Medical Oncology at the Bank of Cyprus Oncology Centre in Nicosia, a post he has held since 1999. He is also an Assistant Professor at St. George’s Medical School, University of London at the University of Nicosia Campus. He obtained his medical degree from Charing Cross and Westminster Medical School, University of London in 1988. Dr Papamichael trained in internal medicine and obtained his Membership of the Royal Colleges of Physicians (MRCP) in 1992 – he became a Fellow 10 years later. His training in Medical Oncology took place at the Royal Marsden and St Bartholomew’s Hospitals in London. Dr Papamichael is an American Society of Clinical Oncology (ASCO) Merit Award winner. He has participated in a number of industry sponsored studies as well as clinical trials coordinated by the European Organization for Research and Treatment of Cancer and the UK Medical Research Council/National Cancer Research Institute.
Dr Papamichael’s main clinical interests include gastrointestinal cancer, and cancer in the elderly. He has published his work in a number of peer-reviewed international journals. He is a member of ASCO, the European Society of Medical Oncology (ESMO), and the International Society of Geriatric Oncology (SIOG). Recently he headed a Task Force responsible for developing recommendations for the management of colorectal cancer in the elderly on behalf of SIOG. He is a member of the ESMO metastatic colorectal cancer guidelines committee, the ESMO GI faculty and co-chairman of an ESMO-SIOG working group.
Youssef Zeidan is the director of the radiation oncology training program at the American University of Beirut . He received his dual MD/PhD degree from the Medical University of South Carolina in 2009. This was followed by four years of residency training in Radiation Oncology at Stanford University (2010-2014) where he served as Chief resident (2013-2014). He was appointed as Assistant Professor of Radiation Oncology at the University of Miami ( 2014-2016) where he directed the radiobiology program. Along with several other co-investigators, he authored more than 30 peer-reviewed publications in the field. This work was recognized by several grants and awards from the radiological society of North America (RSNA) and the American Society for Radiation Oncology (ASTRO).
Nuria Kotecki is a medical oncologist graduated from Lille 2 University of Health and Law in 2014 and currently working at Jules Bordet Institute, in Brussels. During her internship, she has been trained in the clinical development of new cancer drugs at the Jules Bordet Institut. Her main fields of activity and research interests are breast cancer and development of innovative medical therapeutics for solid tumor patients. She has participated in several clinical trials from phase I to later phases. Dr Nuria Kotecki is a member of different scientific organisations including ASCO, ESMO and AACR. She has authored and co-authored articles in national and international papers as well as many abstracts in congress.
Dr Carlos GOMEZ-ROCA, MD, is tenure-track and full-time cancer specialist at the Institut Universitaire du Cancer de Toulouse (IUCT), France. As a medical oncologist, he contributes toward potential therapeutic treatments for cancer, leading as principal investigator or co-investigator more than 30 early phase clinical trials, especially in precision medicine and immune-oncology. As a scientist, his main research interest translational research interest is the immune cross-talk between lesions in metastatic disease and biomarkers of response and toxicity. Dr Gomez-Roca is Faculty at the cancer research committee at ESMO, and member of ASCO and AACR. He has contributed to over 40 peer-reviewed publications, including in JCO, Lancet Oncology and Clinical Cancer Research. His education includes being trained as internal medicine specialist (University of Buenos Aires) and medical oncology (Paris Medical School).
Hans Prenen is Deputy Head of the Oncology Department and Director of the Clinical Trial Management Program at the University Hospital Antwerp, Belgium. He is currently an Associate Professor of Medicine at the University of Antwerp as well as a Senior Clinical Investigator of the Belgian Foundation against Cancer. As oncologist, he is very active in both clinical as well as translational research. Prof. Prenen is a member of several scientific organizations including the BSMO (elected board member since 2015), ESMO and the EORTC. Moreover, he’s regularly invited to national and international meetings and has published more than 100 peer reviewed scientific papers.
Martijn Lolkema is board certified medical oncologist at the Erasmus MC Cancer Institute in Rotterdam. He has completed an MD/PhD program in 2008 and received a Dutch Cancer Foundation award to receive additional research training abroad. He visited the UK to perform research on drug development and translational research using model systems such as genetically engineered mice. In 2010 he started is first position at the UMC Utrecht where he was intimately involved in designing and building a national collaborative group to implement Next Generation Sequencing for cancer patients: the Center for Personalized Cancer Treatment (CPCT). Moreover, he chaired the early trials unit in Utrecht and was intimately involved in the development of novel drugs.
In 2014 Dr. Lolkema joined the Erasmus MC Cancer Institute in Rotterdam to continue his work on drug development and the CPCT. The focus of his clinical and translational research is to understand the factors that determine treatment response and resistance in prostate cancer.
Filippo de Braud, MD, is currently Full Professor of Medical Oncology and Director of the School of Specialization in Medical Oncology, Università degli Studi di Milano, Italy, Director of Medical Oncology and Hematology Department, Director of Medical Oncology Division of the Istituto Nazionale dei Tumori, Milan, where his principal area of expertise is clinical research in oncology.
He leads researchers in new drugs development (Phase I and early Phase II studies) and teaches medical oncology as full professor at Università degli Studi di Milano.
Since 2000, he has been appointed Scientific Advisor and Member of Committee at Italian Medicine Agency AIFA, Ministry of Health, and several Pharmaceutical Companies.
Prof. de Braud is the author or coauthor of over 420 publications in medical oncology.
To be more efficient and to work on different topics, each member can choose to join a working group. The aim of the working groups is to share thoughts and ideas in order to develop future innovative studies for the Network.
Unmet medical needs projects (e.g. brain metastasis…).
New drugs development from phase I to later phases trials (e.g. randomized phase II studies).
“Out of the box” projects are encouraged among all these WGs, with innovative, original trial designs, treatment strategies and topics.
The results of the discussions are shared at each biannual Oncodistinct meeting.
Young investigators are encouraged to join the network and to take leading positions. This contributes to have an interesting knowledge-sharing and to exchange experiences regarding clinical trials and support them for their own projects.
Interact and cooperate with other members of Oncodistinct.
Bring a scientific input and participate to translational research activities related to Oncodistinct clinical studies.
The Oncodistinct Patient Advisory Panel (OPAP) aims to provide researchers and physician-investigators with another perspective on issues related to oncology research.
The mission of OPAP is to improve the relevance and impact of Oncodistinct research projects by involving patients, since the early stages of the development of clinical research protocols. Composed of patients, the main activities of OPAP imply to review and collect opinions on research protocols under development, and to proofread patient information documents and consent forms.